Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Migraine: later-stage trial registry
40 of 105 indexed Migraine trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #125 of 28,707 conditions by registered trial count.
105 US clinical trials · 40 currently recruiting · #125 of 28,707 conditions by registered trial count
Migraine: 105 US clinical trials tracked, 40 recruiting.
Migraine is the subject of 105 registered US clinical trials on ClinicalTrials.gov, 40 of them currently open to new participants. 33 are in Phase 3-4 (later-stage) and 20 in Phase 1-2 (earlier-stage). The most active sponsor is Pfizer, running 7 of these trials.
Enrollment posture brief
Registry condition migraine
OPEN 40 | RECR 38% | LATE 33 | EARLY 20 | RANK #125 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Behavior, Health (38% recruiting · 21 trials)
Migraine lists 40 open slots (38% of 105 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Migraine on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Migraine recruits in line with its size-band peers.
40 of 105 indexed trials (38.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Migraine trials is spread across many organizations.
Pfizer accounts for 7 of 105 trials (6.7%). 59 distinct sponsors appear on at least one study for this condition label.
-
Typical Migraine enrolment sits around 127 participants.
Median target enrolment is 127 among the 103 trials that report a genuine target (sentinel values excluded). 42 of those (40.8%) plan for fewer than 100 participants.
-
Migraine research is mostly interventional.
85 interventional and 20 observational studies make up this index (81% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
105 total, page 2 of 3
Inhaled IAV vs Inhaled Eucalyptus for the Treatment of Nausea With Acute Migraine
HonorHealth Research Institute
NCT05175521
Exploring the Effect of the Transcendental Meditation® Technique on Migraine Frequency and Functionality: A Single Arm Study
Maharishi International University
NCT06695156
Migraine and CVD Risk in Women
University of Pennsylvania
NCT03081390
Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy
Pfizer
NCT05198245
Randomized Trial in Adult Participants With Acute Migraines
Pfizer
NCT04571060
Family Study of Affective and Anxiety Spectrum Disorders
National Institute of Mental Health (NIMH)
NCT00071786
A Study of Lasmiditan (LY573144) Over Four Migraine Attacks
Eli Lilly and Company
NCT03670810
Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults
Pfizer
NCT03732638
A Phase III Trial of e-TNS for the Acute Treatment of Migraine
Cefaly Technology
NCT03465904
A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine
Eli Lilly and Company
NCT05127486
Study of Two Digital Therapeutics for the Prevention of Episodic Migraine
Click Therapeutics
NCT05853900
Prevention Study in Adult Patients Suffering From Migraine Headaches
XenoPort
NCT00742209
Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine
Amgen
NCT04252742
A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents
Teva Branded Pharmaceutical Products R&D
NCT04530110
An Observational Study to Assess Change in Disease Activity When Ubrogepant Tablets Are Combined With Atogepant Tablets to Treat Migraine in Adult Participants
AbbVie
NCT05653986
Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine
AOBiome
NCT03488563
The Safety and Efficacy of Divalproex Sodium Extended-Release Tablets in Migraine Prophylaxis: A Study in Adolescents
Abbott
NCT00195741
Identifying Factors Underlying the Discontinuation of Triptans
Mayo Clinic
NCT00890357
A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age
Teva Branded Pharmaceutical Products R&D
NCT04458857
A Study of Rizatriptan Co-Administered With Acetaminophen for the Treatment of Acute Migraine
Diamond Headache Clinic
NCT00300924
Two Rizatriptan Prescribing Portions for Treatment of Migraine
Clinvest
NCT00397254
Treatment for Migraines With an Implantable Device
Boston Scientific Corporation
NCT00286078
Effect of Catheter Ablation on Clinical Course of Migraine in AF Patients With or Without Previous History of Migraine
Texas Cardiac Arrhythmia Research Foundation
NCT01391091
Real-world Impact of Erenumab on Sick-leaves, Health Care Resource Use and Comorbidities.
Novartis Pharmaceuticals
NCT05375097
Magnesium Versus Prochlorperazine Versus Metoclopramide for Migraines
Wake Forest University Health Sciences
NCT05967442
Hydromorphone Versus Prochlorperazine + Diphenhydramine for Acute Migraine
Montefiore Medical Center
NCT02389829
Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)
Click Therapeutics
NCT06004388
Treximet Early Intervention Adolescent Migraine
Premiere Research Institute
NCT01016678
Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)
Axsome Therapeutics
NCT05550207
A Complex Contraception Registry
University of California, San Diego
NCT02219269
Efficacy of Inhaled Cannabis for Acute Migraine Treatment
University of California, San Diego
NCT04360044
CHOCOlate MeLatonin for AdolescenT MigrainE
Amy Gelfand
NCT03597529
Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults
Manistee Therapeutics
NCT06728553
ACT for High Frequency Migraine; A Virtual Mindfulness Intervention
Brigham and Women's Hospital
NCT05003362
A Study to Assess an Auto-injector Being Used to Treat a Migraine Attack
Pfizer
NCT00510419
A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist
Eli Lilly and Company
NCT04294147
Integrative Migraine Pain Alleviation Through Chiropractic Therapy
Harvard University Faculty of Medicine
NCT03177616
Effect of Osteopathic Manipulative Treatment for Patients With Chronic Headache
Western University of Health Sciences
NCT01332864
A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
Acorda Therapeutics
NCT02905227
Abortive Treatment of Migraine With the Cefaly® Abortive Program Device
Cefaly Technology
NCT03217968
A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants
H. Lundbeck A/S
NCT05304910
A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
Satsuma Pharmaceuticals
NCT03874832
Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants
Eli Lilly and Company
NCT03076970
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
Allergan
NCT04179474
Metformin for the Prevention of Episodic Migraine (MPEM)
Mayo Clinic
NCT02593097
Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fed Conditions
Roxane Laboratories
NCT01161654
STOPAIN in the Treatment of a Single Migraine Attack
Thomas Jefferson University
NCT01687101
Non-Invasive Neurostimulation For the Relief of Symptoms Associated With Migraine
ElectroCore
NCT01532830
Greater Occipital Nerve Block With Bupivacaine for Acute Migraine
Montefiore Medical Center
NCT02665273
An Exploratory Prospective Trial of Rescue Acupuncture for the Treatment of Acute Migraine
Mike O'Callaghan Military Hospital
NCT02764996
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 12 |
| Phase 3 | 20 |
| Phase 4 | 13 |
Top Sponsors
Named interventions
Most-linked intervention names on Migraine records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Migraine trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Migraine page
105 registered trials, 40 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 40 Migraine trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Pfizer sponsors the most Migraine trials on record, review their full trial history before evaluating a specific study. See Pfizer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Migraine condition card totals 105 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.